Data from the company’s Phase II HORIZON study and Phase I/II ANCHOR study evaluating the company’s novel candidate melflufen have been selected as poster presentations at the 2019 American Association for Cancer Research (AACR) Annual Meeting.
The company’s data demonstrate tolerability and high level of activity associated with melflufen in relapsed/refractory multiple myeloma (RRMM) patients and early signs of high efficacy are encouraging.
“Our rigorous clinical development program is initially focused on our first-in-class candidate melflufen, which is currently being studied in global Phase II studies and the Phase III OCEAN study,” said Jakob Lindberg, CEO of Oncopeptides. “We are extremely pleased that these data have been selected for poster presentation at AACR, following their initial presentation at the ASH 2018 Annual Meeting, and believe that this further validates the promise that melflufen holds for the treatment of patients with advanced multiple myeloma whose treatment options are limited.”
Melflufen’s novel mechanism of action works by eliciting increased cytotoxicity in target multiple myeloma (MM) cells and substantially reduced off-target cell toxicity. Melflufen is in a pivotal Phase III study, OCEAN, for its initial indication in RRMM under a Special Protocol Assessment from the US Food and Drug Administration (FDA).
Based on ongoing preclinical studies, Oncopeptides is also exploring the potential for the use of melflufen, or other peptide-conjugated drugs, to treat various cancers beyond MM.
Photo of Jacob Lindberg: Oncopeptides